FDA Approves Ripretinib for Advanced GISTs FDA Approves Ripretinib for Advanced GISTs

The oral therapy is the first-ever drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumors (GISTs).FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news